Broader indication for AstraZeneca and Daiichi Sankyo's Enhertu across Europe

19 July 2022
astrazeneca_big-1

AstraZeneca (LSE: AZN) and Daiichi Sankyo’s (TYO: 4568) Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.

This approval broadens the indication for the HER2-directed antibody drug conjugate across Europe to earlier use in HER2-positive metastatic breast cancer.

"Potential for this medicine to set a new benchmark in the treatment of HER2-positive metastatic breast cancer"The submission was based on the DESTINY-Breast03 results in which Enhertu demonstrated a 72% reduction in the risk of disease progression or death versus trastuzumab emtansine, a drug developed under the brand name Kadcyla by the Roche (ROG: SIX) subsidiary Genentech.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology